XSWX:RLF (Switzerland)  
Relief Therapeutics Holding SA logo

Relief Therapeutics Holding SA

CHF 0.03 (+0.34%) Dec 9
P/E:
At Loss
P/B:
0.76
Market Cap:
CHF 122.85M ($ 131.39M)
Enterprise V:
CHF 95.80M ($ 102.46M)
Volume:
2.87M
Avg Vol (2M):
3.59M
Also Trade In:
Volume:
2.87M
Market Cap CHF:
122.85M
Market Cap $:
131.39M
PE Ratio:
At Loss
Avg Vol (2-Month):
3.59M
Enterprise Value CHF:
95.80M
Enterprise Value $:
102.46M
PB Ratio:
0.76

Business Description

Description
Relief Therapeutics Holding SA is a based drug development company focusing on clinical stage projects, primarily developing drugs of natural human origin. It is engaged in its operations for diabetic complications and respiratory diseases. The company is focused on developing drug candidates namely, Aviptadil and Atexakin alfa. Aviptadil is a biologically active endogenous human peptide that possesses anti-proliferative, anti-inflammatory, and immune regulatory activities. Atexakin alfa is a low dosage formulation of interleukin-6 that exhibits functions in diverse tissues and organs. The group operates its functions in Switzerland.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt 10.58
Equity-to-Asset 0.73
Debt-to-Equity 0.02
Debt-to-EBITDA -0.06
Piotroski F-Score 1/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0.39
Distress
Grey
Safe
Beneish M-Score 1.23
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year Book Growth Rate 63.9

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 54.96
9-Day RSI 51.4
14-Day RSI 50.9
6-1 Month Momentum % -12.12
12-1 Month Momentum % -49.84

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 2.8
Quick Ratio 2.78
Cash Ratio 2.39
Days Inventory 5.1
Days Sales Outstanding 68.02
Days Payable 47.29

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -25.3

Profitability Rank

Name Current Vs Industry Vs History
Gross Margin % -211.49
Operating Margin % -618.71
Net Margin % -708.93
ROE % -29.88
ROA % -21.36
ROIC % -20.64
ROC (Joel Greenblatt) % -1525.65
ROCE % -24